Circulating FGF21 proteolytic processing mediated by fibroblast activation protein

Biochemical Journal

Volumn 473, Issue 5, 2016, Pages 605-614

  Zhen, Eugene Y ^a   Jin, Zhaoyan ^a   Ackermann, Bradley L ^a   Thomas, Melissa K ^a   Gutierrez, Jesus A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Dipeptidyl peptidase IV; Fibroblast activation protein; Fibroblast growth factor 21; Post transcriptional processing; Prolyl peptidase

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; FIBROBLAST ACTIVATION PROTEIN; FIBROBLAST GROWTH FACTOR 21; PROLINE; PROTEINASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BODY MASS; HUMAN; IC50; IMMUNOPRECIPITATION; IN VITRO STUDY; MASS SPECTROMETRY; NONHUMAN; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; ANIMAL; FIBROBLAST; INSULIN RESISTANCE; LIPID METABOLISM;

ANIMALS; FIBROBLASTS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS;

EID: 84975144995     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20151085     Document Type: Article

References (51)

1. Whiting, D.R., Guariguata, L., Weil, C. and Shaw, J. (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94, 311-321
2. Gimeno, R.E. and Moller, D.E. (2014) FGF21-based pharmacotherapy - potential utility for metabolic disorders. Trends Endocrinol. Metab. 25, 303-311
3. Adams, A.C., Halstead, C.A., Hansen, B.C., Irizarry, A.R., Martin, J.A., Myers, S.R., Reynolds, V.L., Smith, H.W., Wroblewski, V.J. and Kharitonenkov, A. (2013) LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS One 8, e65763
4. Veniant, M.M., Komorowski, R., Chen, P., Stanislaus, S., Winters, K., Hager, T., Zhou, L., Wada, R., Hecht, R. and Xu, J. (2012) Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153, 4192-4203
5. Gaich, G., Chien, J.Y., Fu, H., Glass, L.C., Deeg, M.A., Holland, W.L., Kharitonenkov, A., Bumol, T., Schilske, H.K. and Moller, D.E. (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333-340
6. Itoh, N. and Ornitz, D.M. (2011) Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 149, 121-130
7. Suzuki, M., Uehara, Y., Motomura-Matsuzaka, K., Oki, J., Koyama, Y., Kimura, M., Asada, M., Komi-Kuramochi, A., Oka, S. and Imamura, T. (2008) betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22, 1006-1014
8. Kharitonenkov, A., Dunbar, J.D., Bina, H.A., Bright, S., Moyers, J.S., Zhang, C., Ding, L., Micanovic, R., Mehrbod, S.F., Knierman, M.D. et al. (2008) FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell Physiol. 215, 1-7
9. Adams, A.C., Yang, C., Coskun, T., Cheng, C.C., Gimeno, R.E., Luo, Y. and Kharitonenkov, A. (2012) The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2, 31-37
10. Micanovic, R., Raches, D.W., Dunbar, J.D., Driver, D.A., Bina, H.A., Dickinson, C.D. and Kharitonenkov, A. (2009) Different roles of N- and C-termini in the functional activity of FGF21. J. Cell Physiol. 219, 227-234
11. Yie, J., Hecht, R., Patel, J., Stevens, J., Wang, W., Hawkins, N., Steavenson, S., Smith, S., Winters, D., Fisher, S. et al. (2009) FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 583, 19-24
12. Hager, T., Spahr, C., Xu, J., Salimi-Moosavi, H. and Hall, M. (2013) Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Anal. Chem. 85, 2731-2738
13. Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y.Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.C., Graham, M. et al. (2009) Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models - association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 297, E1105-E1114
14. Kharitonenkov, A., Wroblewski, V.J., Koester, A., Chen, Y.F., Clutinger, C.K., Tigno, X.T., Hansen, B.C., Shanafelt, A.B. and Etgen, G.J. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148, 774-781
15. Kharitonenkov, A., Beals, J.M., Micanovic, R., Strifler, B.A., Rathnachalam, R., Wroblewski, V.J., Li, S., Koester, A., Ford, A.M., Coskun, T. et al. (2013) Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One 8, e58575
16. Hecht, R., Li, Y.S., Sun, J., Belouski, E., Hall, M., Hager, T., Yie, J., Wang, W., Winters, D., Smith, S. et al. (2012) Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS One 7, e49345
17. Mu, J., Pinkstaff, J., Li, Z., Skidmore, L., Li, N., Myler, H., Dallas-Yang, Q., Putnam, A.M., Yao, J., Bussell, S. et al. (2012) FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61, 505-512
18. Xu, J., Bussiere, J., Yie, J., Sickmier, A., An, P., Belouski, E., Stanislaus, S. and Walker, K.W. (2013) Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug. Chem. 24, 915-925
19. Camacho, R.C., Zafian, P.T., Achanfuo-Yeboah, J., Manibusan, A. and Berger, J.P. (2013) Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. Eur. J. Pharmacol. 715, 41-45
20. Tsai, T.Y., Yeh, T.K., Chen, X., Hsu, T., Jao, Y.C., Huang, C.H., Song, J.S., Huang, Y.C., Chien, C.H., Chiu, J.H. et al. (2010) Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein. J. Med. Chem. 53, 6572-6583
21. Santos, A.M., Jung, J., Aziz, N., Kissil, J.L. and Pure, E. (2009) Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 119, 3613-3625
22. Kojima, K., Kinoshita, H., Kato, T., Nagatsu, T., Takada, K. and Sakakibara, S. (1979) A new and highly sensitive fluorescence assay for collagenase-like peptidase activity. Anal. Biochem. 100, 43-50
23. Edosada, C.Y., Quan, C., Tran, T., Pham, V., Wiesmann, C., Fairbrother, W. and Wolf, B.B. (2006) Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett. 580, 1581-1586
24. Lee, K.N., Jackson, K.W., Terzyan, S., Christiansen, V.J. and McKee, P.A. (2009) Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design. Biochemistry 48, 5149-5158
25. Galman, C., Lundasen, T., Kharitonenkov, A., Bina, H.A., Eriksson, M., Hafstrom, I., Dahlin, M., Amark, P., Angelin, B. and Rudling, M. (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 8, 169-174
26. Angelin, B., Larsson, T.E. and Rudling, M. (2012) Circulating fibroblast growth factors as metabolic regulators - a critical appraisal. Cell Metab. 16, 693-705
27. Umberger, T.S., Sloan, J.H., Chen, J., Cheng, C., Siegel, R.W., Qian, Y., Troutt, J.S. and Konrad, R.J. (2014) Novel sandwich immunoassays for the measurement of total and active FGF21. Bioanalysis 6, 3283-3293
28. Rosenblum, J.S. and Kozarich, J.W. (2003) Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr. Opin. Chem. Biol. 7, 496-504
29. Hong, W.J. and Doyle, D. (1988) Membrane orientation of rat gp110 as studied by in vitro translation. J. Biol. Chem. 263, 16892-16898
30. Lee, K.N., Jackson, K.W., Christiansen, V.J., Lee, C.S., Chun, J.G. and McKee, P.A. (2006) Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 107, 1397-1404
31. Abbott, C.A., Yu, D.M., Woollatt, E., Sutherland, G.R., McCaughan, G.W. and Gorrell, M.D. (2000) Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur. J. Biochem. 267, 6140-6150
32. Olsen, C. and Wagtmann, N. (2002) Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene 299, 185-193
33. Underwood, R., Chiravuri, M., Lee, H., Schmitz, T., Kabcenell, A.K., Yardley, K. and Huber, B.T. (1999) Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J. Biol. Chem. 274, 34053-34058
34. Cunningham, D.F. and O'Connor, B. (1997) Proline specific peptidases. Biochim. Biophys. Acta 1343, 160-186
35. Fulop, V., Szeltner, Z. and Polgar, L. (2000) Catalysis of serine oligopeptidases is controlled by a gating filter mechanism. EMBO Rep. 1, 277-281
36. Mentlein, R. (1988) Proline residues in the maturation and degradation of peptide hormones and neuropeptides. FEBS Lett. 234, 251-256
37. Drucker, D.J. (2002) Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122, 531-544
38. Huang, C.H., Suen, C.S., Lin, C.T., Chien, C.H., Lee, H.Y., Chung, K.M., Tsai, T.Y., Jiaang, W.T., Hwang, M.J. and Chen, X. (2011) Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate. J. Biochem. 149, 685-692
39. Durinx, C., Lambeir, A.M., Bosmans, E., Falmagne, J.B., Berghmans, R., Haemers, A., Scharpe, S. and De Meester, I. (2000) Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur. J. Biochem. 267, 5608-5613
40. Niedermeyer, J., Garin-Chesa, P., Kriz, M., Hilberg, F., Mueller, E., Bamberger, U., Rettig, W.J. and Schnapp, A. (2001) Expression of the fibroblast activation protein during mouse embryo development. Int. J. Dev. Biol. 45, 445-447
41. Scanlan, M.J., Raj, B.K., Calvo, B., Garin-Chesa, P., Sanz-Moncasi, M.P., Healey, J.H., Old, L.J. and Rettig, W.J. (1994) Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. U.S.A. 91, 5657-5661
42. Tchou, J. and Conejo-Garcia, J. (2014) Fibroblast activation protein, a potential diagnostic and therapeutic target for cancer-reply. Hum. Pathol. 45, 1553-1554
43. Hamson, E.J., Keane, F.M., Tholen, S., Schilling, O. and Gorrell, M.D. (2014) Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin. Appl. 8, 454-463
44. Keane, F.M., Nadvi, N.A., Yao, T.W. and Gorrell, M.D. (2011) Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. FEBS J. 278, 1316-1332
45. Lee, K.N., Jackson, K.W., Christiansen, V.J., Chung, K.H. and McKee, P.A. (2004) A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 103, 3783-3788
46. Levy, M.T., McCaughan, G.W., Abbott, C.A., Park, J.E., Cunningham, A.M., Muller, E., Rettig, W.J. and Gorrell, M.D. (1999) Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 29, 1768-1778
47. Christiansen, V.J., Jackson, K.W., Lee, K.N. and McKee, P.A. (2007) Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch. Biochem. Biophys. 457, 177-186
48. Osborne, B., Yao, T.W., Wang, X.M., Chen, Y., Kotan, L.D., Nadvi, N.A., Herdem, M., McCaughan, G.W., Allen, J.D., Yu, D.M. et al. (2014) A rare variant in human fibroblast activation protein associated with ER stress, loss of enzymatic function and loss of cell surface localisation. Biochim. Biophys. Acta 1844, 1248-1259
49. Chung, K.M., Cheng, J.H., Suen, C.S., Huang, C.H., Tsai, C.H., Huang, L.H., Chen, Y.R., Wang, A.H., Jiaang, W.T., Hwang, M.J. and Chen, X. (2010) The dimeric transmembrane domain of prolyl dipeptidase DPP-IV contributes to its quaternary structure and enzymatic activities. Protein. Sci. 19, 1627-1638
50. Collins, P.J., McMahon, G., O'Brien, P. and O'Connor, B. (2004) Purification, identification and characterisation of seprase from bovine serum. Int. J. Biochem. Cell Biol. 36, 2320-2333
51. Wesley, U.V., Albino, A.P., Tiwari, S. and Houghton, A.N. (1999) A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J. Exp. Med. 190, 311-322